Sage did started, as expected.
Now, the question is how many options did they converted in 02?
Leonard S. Schleifer, M.D., Ph.D. 1,769,340 619,949 5.4%
(8) Includes 523,370 shares of Common Stock purchasable upon the exercise of options granted pursuant to the 1990 and 2000 Long-Term Incentive Plans which are exercisable or become so within sixty days from April 19, 2002 and 1,570 shares of Common Stock held in an account under the Company's 401(k) Savings Plan. Includes 1,800 shares of Common Stock held in trust for the benefit of Dr. Schleifer's two sons, of which Dr. Schleifer disclaims beneficial ownership. Excludes 4,000 shares of Common Stock held by the Schleifer Family Foundation, a charitable foundation, of which Dr. Schleifer disclaims beneficial ownership.
Murray A. Goldberg 150,382 (16)
(16) Includes 115,531 shares of Common Stock purchasable upon the exercise of options granted pursuant to the 1990 and 2000 Long-Term Incentive Plans which are exercisable or become so within sixty days from April 19, 2002 and 1,570 shares held in an account under the Company's 401(k) Savings Plan.
George D. Yancopoulos, M.D., Ph.D. 42,75(7) 663,245 (15)
(15) Includes 633,550 shares of Common Stock purchasable upon the exercise of options granted pursuant to the 1990 and 2000 Long-Term Incentive Plans which are exercisable or become so within sixty days from April 19, 2002 and 1,570 shares of Common Stock held in an account under the Company's 401(k) Savings Plan.
<<REGENERON PHARMACEUTICALS INC (REGN) form 8-K
ITEM 5. OTHER EVENTS.
The Company has been advised that on July 10, 2002, Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, entered into a trading plan complying with SEC Rule 10b5-1 and the Company's insider trading policy. Under Rule 10b5-1, directors and officers may adopt a prearranged contract or plan for the sale of Company securities under specified conditions and times.
Dr. Schleifer's plan calls for the sale of a minimum of 31,000 shares and potentially up to approximately 484,000 shares of Company common stock between September 1, 2002 and August 31, 2003 contingent upon the Company's share price reaching certain designated prices up to $46.00 per share. The shares to be sold under the plan would come from the exercise of stock options issued under the Company's Long-Term Incentive Plans. Dr. Schleifer intends to sell a portion of the shares under the plan to reduce Alternative Minimum Tax relating to the exercise of incentive stock options earlier in the year.
Murray A. Goldberg, Senior Vice President, Finance & Administration and Chief Financial Officer, and George D. Yancopoulos, M.D., Ph.D., Executive Vice President, Chief Scientific Officer, and President, Regeneron Research Laboratories, and other Company officers and directors have also adopted 10b5-1 plans to sell shares of Company common stock under specified conditions and times. In addition, P. Roy Vagelos , M.D., Chairman of the Company's Board of Directors, has adopted 10b5-1 plans to allow certain of his shares of Company common stock to be gifted to a charitable foundation. We expect that directors and officers of the Company will adopt additional 10b5-1 plans in the future consistent with the Company's insider trading policy. Except as may become required by law, the Company does not undertake to report modifications, terminations or other activities under these plans, nor the establishment of future 10b5-1 plans by these or other Company directors or officers.>> |
